Canine Atopic Dermatitis Market is Segmented By Treatment Type (Monoclonal Antibody, Glucocorticoids, Immuno-suppressants, Other Treatment Types), By Route of Administration(Injectable, Topical, Oral), By Distribution Channel(Veterinary hospitals, Pet clinics, Pharmacies & drug stores, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview
Canine Atopic Dermatitis Market is expected to reach at a CAGR 8.46% during the forecast period (2024-2031). Canine atopic dermatitis is the chronic inflammation on the skin of dogs, often caused by allergens such as pollens, flea or other insect bites, and food ingredients.
Market Summary
| Metrics | Details |
| Market CAGR | 8.46% |
| Segments Covered | By Treatment Type, By Route of Administration, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More: Downlaod Sample
Market Dynamics
The global canine atopic dermatitis market growth is driven by the rise in prevalence of canine atopic dermatitis, rise in awareness about early signs & symptoms of allergic reaction in animals and development of advanced therapeutic methods to control symptoms, rise in pollution associated with allergens level.
Increasing R&D activities is expected to drive the growth in the forecast period
Environmental factors are responsible for many allergies and diseases, expected to drive market growth. Increasing R&D activities are also expected to drive the market. For instance, in January 2020, Boragen partnered with one of the global leading animal health companies, exclusively for the R&D activity related to developing new treatment of canine atopic dermatitis. Also, as per the research article published in Veterinary Medicine and Science, 2020, Luteolin was evaluated to study the antioxidant effect in treating canine atopic dermatitis. The results revealed that Luteolin was able to drastically minimize the levels of IL‐33, IL 1β, IL‐6, and IL‐8 and suggested that Luteolin is a promising agent in pharmacological treatment for canine atopic dermatitis. Hence, such factors are expected to boost the canine atopic dermatitis market during the forecast period.
Drug-induced severe hypersensitivity reactions are likely to hamper the market growth
Several drugs cause serious adverse reactions which can further alleviate allergic reactions. Improper management of canine atopic dermatitis in terms of dosage, administration of drugs, and drug combination can also hamper the growth of the global market.
COVID-19 Impact Analysis
The impact of COVID-19 on the canine atopic dermatitis market is expected to be significant. As per the Centers for Disease Control and Prevention data, cats, dogs, and a few other types of animals are at potential risk of acquiring this virus. Several studies are still ongoing concerning the connection between animals and human transmission of this virus. However, governments have been taking measures to mitigate the supply of medicines. For instance, the European Medicines Agency issued guidance for companies responsible for veterinary medicines regarding the adaptations to the regulatory framework, primarily to address the challenges faced during the pandemic. IN July 2020, the Centers for Disease Control and Prevention recommended certain guidelines to the veterinary professionals to treat companion animals during the COVID-19 pandemic.
Additionally, as per the research article published in Humanities and Social Sciences Communications, 2020, the total number of online searches on the Yad4 website was 221,959 in April 2020 compared to 72,703 in April 2019. The study revealed the growing rate of dog adoption during the pandemic. Therefore, the canine atopic dermatitis market is expected to be impacted during the pandemic due to such factors.
Market Segment Analysis
The monoclonal antibodies segment is expected to hold the largest share in this market segment
The monoclonal antibodies segment is expected to exhibit profitable market growth over the forecast period. The major attributable factors are the rising awareness of and the increasing product approvals.
Lokivetmab is a caninized anti–interleukin-31 (IL-31) mAb developed and licensed by Zoetis. It works by neutralizing soluble IL-31 released primarily by lymphocytes. Lokivetmab is effective against atopic dermatitis and allergic dermatitis in dogs. Furthermore, in 2019, Kindred Biosciences developed a monoclonal antibody, Interleukin-31, to treat canine atopic dermatitis. It completed its pilot study and showed a significant outcome. Hence, advancements in products are expected to influence the market positively.
As per the research article published in the Asian Journal of Epidemiology, 2020, the development of monoclonal antibodies is expected to show similar growth in veterinary medicine that aids in providing promising alternative strategies to overcome the obstacles of drug resistance, adverse effects of drugs, drug residue, and other complications associated with the traditional veterinary drugs. Thus, due to the aforementioned factors, therapeutic monoclonal antibodies are gaining importance in treating allergic conditions in dogs, which may boost market growth over the forecast period.
Market Geographical Share
North America region holds the largest market share of the global canine atopic dermatitis market
North America is expected to be a dominant region for the canine atopic dermatitis market, owing to increased spending in R&D activities, the high concentration of key players in the market, and the high rate of households with dog ownership in the region. According to the Animal Health Institute, the US animal health industry serves around 640 million food animals and 383 million companion animals.
As per the Canadian Animal Health Institute (CAHI), in 2018, there were nearly 8.2 million dogs in Canada. Over a decade, dog ownership has increased significantly in the country. As per the American Pet Products Association, nearly 63.4 million households in the United States owned a dog in 2020. Additionally, dogs occupy 63.4% of the pet share in the United States, and owners spend an average of around USD 1,380 on pet dogs’ basic expenses. Thus, high dog ownership in the region is expected to drive market growth.
Also, the new product approvals and strategic alliances by key players are expected to boost the studied market. For instance, in October 2020, Elanco signed an agreement to acquire Bayer’s Animal Health business in a transaction valued at USD 7.6 billion. Thus, the North American canine atopic dermatitis market is expected to register significant growth over the forecast period due to the factors mentioned above.
Market Competitive Landscape
The global canine atopic dermatitis market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Zoetis, Elanco, Virbac, Toray Industries Inc., Dechra Veterinary Products, Kindred Biosciences Inc., Ceva, Vetoquinol S.A, Novartis AG. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, in October 2020, Virbac received US FDA approval for its CYCLAVANCE (cyclosporine oral solution) USP MODIFIED to control atopic dermatitis in dogs weighing at least 4 lbs (1.8 kg).
Global Canine Atopic Dermatitis Market – Key Companies to Watch
Zoetis
Overview: Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. It includes seven product categories: vaccines, anti-infectives, parasiticides, dermatology products, medicated feed additives, animal health diagnostics, other pharmaceuticals.
Product Portfolio: CYTOPOINT is effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.
Key Developments: In September 2020, Zoetis received a variation to the terms of the marketing authorization for the veterinary medicinal product, Cytopoint, by the Committee for Medicinal Products for Veterinary Use (CVMP), in which the variation concerns adding a new therapeutic indication for the treatment of pruritus associated with allergic dermatitis in dogs.
